AI English summary of an SEC filing — figures as filed

The company said the Board appointed Victor Bulto as a member of the Board on November 20, 2025, effective December 1, 2025.

8-KDeparture or Appointment of Directors or Certain OfficersFiled Nov 24, 2025Period of report Nov 20, 2025Summary published (UTC) Oct 12, 2026

Key points

AI summary

The company said the Board appointed Victor Bulto as a member of the Board on November 20, 2025, effective December 1, 2025.
The company said Bulto will be entitled to receive compensation for his service on the Board consistent with the company's director compensation program, as described in the company's most recent proxy statement filed with the SEC on April 4, 2025.
The company said Bulto has served as President of Novartis U.S. and a member of the Novartis Executive Committee since April 2022, and has 25 years of experience in healthcare, according to the press release.
In the press release dated November 24, 2025, the company explained that Bulto oversees Novartis' U.S. business, a $20+ billion operation, with responsibility across four key therapeutic areas.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Victor Bulto Appointed to Board, Effective December 1, 2025

The company said the Board appointed Victor Bulto as a member of the Board on November 20, 2025, effective December 1, 2025.

Source · Based on the filing body and exhibits

Director Compensation Consistent with Existing Director Compensation Program

The company said Bulto will be entitled to receive compensation for his service on the Board consistent with the company's director compensation program, as described in the company's most recent proxy statement filed with the SEC on April 4, 2025.

Source · Based on the filing body and exhibits

Bulto's Background as President of Novartis U.S. and Other Roles

The company said Bulto has served as President of Novartis U.S. and a member of the Novartis Executive Committee since April 2022, and has 25 years of experience in healthcare, according to the press release.

Source · Based on the filing body and exhibits

Company Press Release Explains Bulto's Appointment

In the press release dated November 24, 2025, the company explained that Bulto oversees Novartis' U.S. business, a $20+ billion operation, with responsibility across four key therapeutic areas.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.